Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light chain amyloidosis (AL) before stem cell transplantation (ASCT), instead of ASCT in ineligible patients or as salvage. Treatment was a combination of bortezomib (1.5 mg/m(2...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mikhael, Joseph R., Schuster, Steven R., Jimenez-Zepeda, Victor H., Bello, Nancy, Spong, Jacy, Reeder, Craig B., Stewart, A. Keith, Bergsagel, P. Leif, Fonseca, Rafael
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2012
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3557400/
https://ncbi.nlm.nih.gov/pubmed/22331188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-11-390930
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares